RxDoctor Payments Data

Edmond Ghahramani, MD

Family Medicine · Turlock, CANPI 1982800199

Payments from drug & device makers

$1,027in general payments, 2019–2025

Across 71 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$267
  • Johnson & Johnson$101
  • Amgen$81
  • Teva Pharmaceuticals USA, Inc.$80
  • Ironwood Pharmaceuticals, Inc$71
  • Amarin Pharma, Inc.$71
  • plus $355 from 11 others

What the payments were for

  • Food & beverage$1,01999%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,027 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$417,993
Medicare patients
721
Services billed
6,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate167$190,984
LinzessLinaclotide119$160,445
JardianceEmpagliflozin89$122,712
OzempicSemaglutide81$105,457
EliquisApixaban117$95,668
MyrbetriqMirabegron97$83,520
TradjentaLinagliptin82$77,422
Breo ElliptaFluticasone/Vilanterol162$76,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$55,200
XareltoRivaroxaban51$53,457
RybelsusSemaglutide25$44,388
Spiriva RespimatTiotropium Bromide44$29,089
FarxigaDapagliflozin Propanediol31$27,834
Incruse ElliptaUmeclidinium Bromide32$21,336
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$12,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$267$229,223215 claims
MerckJanuvia, Janumet$33$203,051180 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta$12$165,393267 claims
AbbVieLinzess$29$160,445119 claims
PfizerEliquis$50$95,668117 claims
Johnson & JohnsonXarelto$101$53,45751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →